New antibody drug shows promise for blocking asthma attacks
NCT ID NCT00983658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a drug called huMAb OX40L in 29 adults with mild allergic asthma. The drug is an antibody designed to block a protein that triggers allergic reactions in the airways. Researchers measured whether it could prevent breathing problems caused by allergens, compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- huMAb OX40L (a lab-made antibody that blocks a protein involved in allergic reactions)
- What this could lead to
- If it works, this could point toward a new treatment to control asthma attacks triggered by allergens.
- What could go wrong
- This is a small, early-phase trial with only 29 people. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
29 people
The number who actually took part.
- Started
-
Sep 2009
- Finished
-
Jan 2011
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Weight between 50 and 125 kg * Mild, stable allergic asthma * History of episodic wheeze and shortness of breath * FEV1 at baseline ≥ 70% of the predicted value * For women of childbearing potential, agreement to use an effective means of contraception while enrolled in the study * For men with partners of childbearing potential, willingness to use condoms with spermicide during treatment * Ability to comprehend and follow all required study procedures * Positive skin prick test to common aeroallergens (e.g., cat, dust, mite, grass, and pollen) * Positive allergen-induced early and late airway bronchoconstriction Exclusion Criteria: * A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry * Acute infection (including viral infection) within the 6 weeks preceding dosing (8 weeks for respiratory infections) or any ongoing chronic infection * History of recurrent bacterial infection as an adult or history or presence of any chronic infectious condition, including (but not limited to), tuberculosis, parasitic infection, etc. * Lung disease other than mild allergic asthma * History of heart, lung, kidney, liver, neurologic or chronic infectious disease * Concomitant disease or condition, which could interfere with the conduct of the study, including, but not limited to, cancer, alcoholism, drug dependency or abuse, or psychiatric disease * History of serious adverse reaction or hypersensitivity to any drug * Pregnancy or lactation or positive serum pregnancy test at screening * Chronic use of any other medication for treatment of allergic lung disease other than short-acting β2-agonists or ipratropium bromide * Current (or history of) treatment with a monoclonal antibody or chimeric biomolecule within the past 5 months (5 half-lives of the drug), including omalizumab * Regular use of tobacco products of any kind or within the previous 6 months, or smoking history \> 10 pack-years
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple breath test cut asthma Flare-Ups?
- Breathing tests face off: can extra lung measurements improve asthma diagnosis?
- The carbon label on your inhaler: can it sway a Doctor's choice?
- Six biologics put to the test in Real-World asthma and COPD care
- Can a digital program help teens with chronic illnesses move to adult care?
- Why do some kids catch every cold? a 1,200-Child study hunts for immune clues